Final Overall Survival (Os) Analysis Of First-Line (1l) Folfox-4 +/- Cetuximab (Cet) In Patients (Pts) With Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) In The Phase 3 Tailor Trial.

JOURNAL OF CLINICAL ONCOLOGY(2018)

引用 4|浏览22
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要